Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pivotal, randomisert, åpen studie av Optune® (tumorbehandlingsfelt) samtidig med RT og TMZ for behandling av nylig diagnostisert GBM (EF-32)

30. september 2026 oppdatert av: NovoCure Ltd.

EF-32: Pivotal, randomisert, åpen undersøkelse av Optune® (tumorbehandlingsfelt, 200 kHz) samtidig med strålebehandling og temozolomid for behandling av nylig diagnostisert glioblastom

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.

The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).

The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.

The study will randomize 950 subjects equally to one of two treatment arms:

  1. Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
  2. Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.

All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.

Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.

After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.

If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.

After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.

Subjects will be required to return to the clinic per the study protocol.

After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.

After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.

Studietype

Intervensjonell

Registrering (Faktiske)

981

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Liège, Belgia, B35, 4000
        • University Hospital Liege - Sart Tilman
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • BC Cancer - Vancouver
    • Nova Scotia
      • Sydney, Nova Scotia, Canada, B1P 1P3
        • Nova Scotia Health Authority
    • Ontario
      • Ottawa, Ontario, Canada
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Canada
        • Princess Margaret Cancer Centre
      • Toronto, Ontario, Canada
        • Sunnybrook Research Institute - Odette Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, H2X1R9
        • CHUM Centre de Recherche
      • Sherbrooke, Quebec, Canada
        • Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
    • Alabama
      • Birmingham, Alabama, Forente stater, 35243
        • Grandview Cancer Center
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Banner MD Anderson Cancer Center
      • Phoenix, Arizona, Forente stater, 85054
        • Mayo Clinic- Arizona
      • Tucson, Arizona, Forente stater, 85719
        • University of Arizona Cancer Center
    • Arkansas
      • Fayetteville, Arkansas, Forente stater, 72762
        • Highlands Oncology Group
    • California
      • Burbank, California, Forente stater, 91505
        • Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
      • Duarte, California, Forente stater, 91010
        • City of Hope National Medical Center
      • Fullerton, California, Forente stater, 92835
        • TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
      • La Jolla, California, Forente stater, 92093
        • University of California at San Diego - Moores Cancer Center
      • Los Angeles, California, Forente stater, 90048
        • Cedars - Sinai Medical Center
      • Los Angeles, California, Forente stater, 90033
        • Norris Comprehensive Cancer Center at USC
      • Newport Beach, California, Forente stater, 92663
        • Hoag Memorial Hospital - Hoag Cancer Center
      • Orange, California, Forente stater, 92868
        • St. Joseph Hospital of Orange
      • Orange, California, Forente stater, 92868
        • University of California - Irvine/UCI Medical Center
      • Palo Alto, California, Forente stater, 94303
        • Stanford University Cancer Institute
      • San Diego, California, Forente stater, 92123
        • Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
      • San Francisco, California, Forente stater, 94143
        • University of California San Francisco Medical Center
      • Santa Monica, California, Forente stater, 90404
        • John Wayne Cancer Institute at St. John's Health Center
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • University of Colorado Cancer Center Anschutz
      • Englewood, Colorado, Forente stater, 80113
        • HCA Research Institute - Blue Sky Neurology - Denver
    • Connecticut
      • Hartford, Connecticut, Forente stater, 06106
        • Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
    • Florida
      • Boca Raton, Florida, Forente stater, 33486
        • Lynn Cancer Institute, Marcus Neuroscience Institute
      • Jacksonville, Florida, Forente stater, 32224
        • Mayo Clinic
      • Jacksonville, Florida, Forente stater, 32207
        • Baptist Health - Jacksonville
      • Orlando, Florida, Forente stater, 32804
        • AdventHealth
      • Orlando, Florida, Forente stater, 32806
        • Orlando Health UF Health Cancer Center
      • Tampa, Florida, Forente stater, 33612
        • H. Lee Moffitt Cancer Center and Research Institute, Inc
    • Georgia
      • Atlanta, Georgia, Forente stater, 30342
        • Northside Hospital, Inc.
      • Atlanta, Georgia, Forente stater, 30309
        • Piedmont Healthcare Brain Tumor Center
      • Atlanta, Georgia, Forente stater, 30322
        • The Emory Clinic - Emory Healthcare - Winship Cancer Institute
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Forente stater, 60617
        • University of Chicago
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46845
        • Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
    • Kansas
      • Topeka, Kansas, Forente stater, 66606
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40241
        • Norton Cancer Institute
      • Louisville, Kentucky, Forente stater, 40202
        • University of Louisville - James Graham Brown Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70810
        • Mary Bird Cancer Center Neuromedical Center
      • New Orleans, Louisiana, Forente stater, 70072
        • LSU Health Sciences Center, New Orleans
      • New Orleans, Louisiana, Forente stater, 70121-2429
        • Ochsner Health System
    • Maine
      • South Portland, Maine, Forente stater, 04106
        • Maine Medical Partners Neurology - Neurosurgery & Spine Associates
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • John Hopkins School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Tufts Medical Center
      • Worcester, Massachusetts, Forente stater, 01655
        • University of Massachusetts Chan Medical School
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan Comprehensive Cancer Center
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55407
        • Abbott Northwestern Hospital - Givens Brain Tumor Center
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • University of Missouri - Ellis Fischel Cancer Center
      • Kansas City, Missouri, Forente stater, 64132
        • Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
      • St Louis, Missouri, Forente stater, 63110
        • Washington University School of Medicine
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03756
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Edison, New Jersey, Forente stater, 08820
        • JFK Neuroscience Institute, HMH JFK University Medical Center
      • Hackensack, New Jersey, Forente stater, 07601
        • Hackensack University Medical Center - John Theurer Cancer Center
      • Neptune City, New Jersey, Forente stater, 07753
        • Jersey Shore University Medical Center
    • New York
      • Lake Success, New York, Forente stater, 11042
        • Northwell Health System Brain Tumor Center
      • New York, New York, Forente stater, 10029
        • Mount Sinai - Icahn School of Medicine
      • New York, New York, Forente stater, 10016
        • NYU Langone - Laura & Issac Perimutter Cancer Center
      • New York, New York, Forente stater, 10032
        • New York Presbyterian - Columbia University
      • Rochester, New York, Forente stater, 14642
        • University of Rochester Medical Center
      • Syracuse, New York, Forente stater, 13210
        • SUNY Upstate Medical University
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599
        • University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Forente stater, 28204
        • Novant Health Cancer Institute Radiation Oncology
      • Greenville, North Carolina, Forente stater, 27834
        • Vidant Medical Center
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Wake Forest Baptist Comprehensive Cancer Center
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Forsyth Medical Center-Novant Health
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • University of Cincinnati Cancer Institute
      • Columbus, Ohio, Forente stater, 43210
        • The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health & Science University (OHSU)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Neuroscience Center, Philadelphia - University of Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Allegheny Health Network Cancer Institute
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • MUSC Radiation Oncology Brain & Spine Tumor Program
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • SCRI - Tennessee Oncology
      • Germantown, Tennessee, Forente stater, 38138
        • West Cancer Center - Germantown
      • Nashville, Tennessee, Forente stater, 37203
        • SCRI - Tennessee Oncology
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Texas Oncology Midtown - Austin Brain Tumor Center
      • Dallas, Texas, Forente stater, 75246
        • Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
      • Fort Worth, Texas, Forente stater, 76104
        • John Peter Smith Health Network - JPS Cancer Center
      • Houston, Texas, Forente stater, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Forente stater, 77030
        • UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
      • Temple, Texas, Forente stater, 76508
        • Baylor Scott & White Medical Center
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • The University of Vermont Medical Center - University of Vermont Cancer Center
    • Washington
      • Seattle, Washington, Forente stater, 98122
        • Swedish Health Services
      • Seattle, Washington, Forente stater, 98109
        • UW Medical Center - Alvord Brain Tumor Center
    • West Virginia
      • Morgantown, West Virginia, Forente stater, 26506
        • West Virginia University Cancer Institute
      • Angers, Frankrike, 49055
        • Institut de cancérologie de l'Ouest
      • Bron, Frankrike, 69677
        • Pierre Wertheimer Hospital
      • Marseille, Frankrike, 13305
        • Hôpital la Timone
      • Nice, Frankrike, 06000
        • University Hospital Nice
      • Paris, Frankrike, 75013
        • Pitié-Salpêtrière University Hospital
      • Saint-Herblain, Frankrike, 44800
        • Institut de cancérologie de l'Ouest
      • Toulouse, Frankrike, 31059
        • University Institute Cancer Toulouse Oncopole
      • Villejuif, Frankrike, 94805
        • Gustave Roussy Institute
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center - Ein Kerem
    • Haifa District
      • Haifa, Haifa District, Israel, 3109601
        • Rambam Medical Center
    • Petah Tikva
      • Petah Tikva, Petah Tikva, Israel, 49100
        • Rabin Medical Center
    • Ramat Gan
      • Ramat Gan, Ramat Gan, Israel, 52621
        • Sheba Medical Center
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 64239
        • Tel Aviv Sourasky Medical Center
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8648
        • Hokkaido University Hospital
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 920-8641
        • Kanazawa University Hospital
    • Saitama
      • Hidaka-shi, Saitama, Japan, 350-1298
        • Saitama Medical University International Medical Center
    • Tokyo-To
      • Mitaka-shi, Tokyo-To, Japan, 181-8611
        • Kyorin University Hospital
      • Shinjuku-ku, Tokyo-To, Japan, 162-8666
        • Tokyo Women's Medical University Hospital
      • Liverpool, Storbritannia, L7 8YA
        • Clatterbridge Cancer Centre
      • London, Storbritannia, SE1 9RT
        • Guy's Hospital
      • London, Storbritannia, W6 8RF
        • Charing Cross Hospital
      • Nottingham, Storbritannia, NG5 1PB
        • Nottingham University Hospitals NHS Trust
      • Preston, Storbritannia, PR29HT
        • Royal Preston Hospital
      • Lausanne, Sveits, CH-1011
        • Lausanne University Hospital
      • Zurich, Sveits, 8091
        • University Hospital Zurich
    • Brno
      • Brno, Brno, Tsjekkia, 656 53
        • Masaryk Memorial Cancer Institute
    • Pilsen
      • Pilsen, Pilsen, Tsjekkia, 305 99
        • University Hospital Plzeň
    • Prague
      • Prague, Prague, Tsjekkia, 150 30
        • Na Homolce Hospital
      • Essen, Tyskland, 45147
        • University Hospital Essen
      • Freiburg im Breisgau, Tyskland, 79106
        • University Medical Center Freiburg
      • Leipzig, Tyskland, 04103
        • University Hospital Leipzig
      • Munich, Tyskland, 81675
        • Rechts der Isar Hospital
      • Tübingen, Tyskland, 72076
        • University Hospital Tübingen
    • Innsbruck
      • Innsbruck, Innsbruck, Østerrike, 6020
        • Innsbruck University Hospital
    • Linz
      • Linz, Linz, Østerrike, 4020
        • Kepler University Hospital
    • State of Salzburg
      • Salzburg, State of Salzburg, Østerrike, 5020
        • University Hospital Salzburg

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

*Age Limits - 18 years or older outside of the US, 22 years or older within the US.

Inclusion Criteria:

  1. Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
  2. Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
  3. Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
  4. Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
  5. Karnofsky performance status ≥ 70
  6. Life expectancy ≥ least 3 months
  7. Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
  8. All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
  9. Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
  10. Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
  11. Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
  12. Is able to have MRI with contrast of the brain

Exclusion Criteria:

  1. Progressive disease (per investigator's assessment)

  2. Infratentorial or leptomeningeal disease

  3. Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study

  4. Pregnancy or breast-feeding.

  5. Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:

    1. Thrombocytopenia (platelet count < 100 x 103/μL)
    2. Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
    3. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
    4. Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
    5. Total bilirubin > 1.5 x upper limit of normal
    6. Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
    7. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
  6. Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.

  7. Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)

  8. History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.

  9. Additional malignancies that are progressing or required active treatment in the last two years.

  10. Admitted to an institution by administrative or court order.

  11. Known allergies to medical adhesives or hydrogel

  12. A skull defect (such as, missing bone with no replacement)

  13. Prior radiation treatment to the brain for the treatment of GBM

  14. Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.

  15. Standard TTFields exclusion criteria include

    1. Active implanted medical devices
    2. Bullet fragments
    3. Skull defects

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Optune® + RT + TMZ for 6 weeks

Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression.

Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.

In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.

In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.

Aktiv komparator: RT +TMZ for 6 weeks

RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression.

Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.

In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.

In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival (OS)
Tidsramme: 5 years

Survival will be measured from the time of randomization until date patient is alive.

5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Survival (PFS)
Tidsramme: 5 years

PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria.

5 years
1- and 2-year survival rates
Tidsramme: 5 years

The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study.

5 years
Overall Radiological response (ORR)
Tidsramme: 5 years

The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response.

5 years
Next progression-free survival (PFS2)
Tidsramme: 5 years

PFS2 will be measured from the time of randomization to second tumor progression.

5 years
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Tidsramme: 5 years

The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study.

5 years
Severity and frequency of adverse events
Tidsramme: 5 years

The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments.

5 years
Quality of Life EORTC Questionnaire
Tidsramme: 5 years

The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement.

5 years
The NANO scale
Tidsramme: 5 years

The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria.

5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. desember 2020

Primær fullføring (Faktiske)

19. februar 2026

Studiet fullført (Faktiske)

19. februar 2026

Datoer for studieregistrering

Først innsendt

9. juli 2020

Først innsendt som oppfylte QC-kriteriene

13. juli 2020

Først lagt ut (Faktiske)

15. juli 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. mars 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere